Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Hepatology. 2019 May 15;70(4):1360–1376. doi: 10.1002/hep.30631

Fig. 5. HNF4A interacts with TET3 in vivo and in vitro.

Fig. 5

(A) RNA-Seq RPKM values of Tet1, Tet2 andTet3 in hepatocytes. (B) Western blot showing expression of TET3 in hepatoblast and hepatocytes with β-Actin control. (C) Immunoprecipitation in HepG2 lysate using anti-HNF4A and negative control (IgG) followed by Western blots for TET3 and HNF4A. (D) Immunoprecipitation on hepatocytes isolated from 3 female livers using anti-HNF4A and negative control (IgG) followed by Western blots for HNF4A and TET3. (E) Immunoprecipitation and Western blot analysis of hepatoblast lysates using anti-HNF4A and IgG antibody to IP and TET3 and HNF4A antibodies to validate interaction. (F) Depiction of proximity ligation assay (PLA) technique (top). PLA on adult (middle) and embryonic liver (bottom) sections using an antibody against HNF4A and TET3 confirm endogenous interaction, shown as yellow dots inside DAPI stained nuclei (Blue).